Le Lézard
Classified in: Health
Subject: SVY

Microbial Identification Market - Expected to Reach USD 3 Billion By 2022


DUBLIN, Dec. 11, 2017 /PRNewswire/ --

The "Microbial Identification Market by Product & Service (Instruments, Consumables, Identification Services), Method (Phenotypic, Proteomics-based, Genotypic), Application (Pharmaceutical, Diagnostic, Environmental) End User - Global Forecast to 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The global microbial identification market is expected to reach USD 3.00 Billion by 2022 from USD 2.18 Billion in 2017, at a CAGR of 6.6%. The market growth is primarily driven by the rising incidence of infectious diseases coupled with epidemic and pandemic outbreaks, increasing food safety concerns, technological advancements in microbial identification techniques, and government initiatives and funding to promote microbial identification.

The global microbial identification market is segmented by product and service, method, application, end user, and regions. By product and service, the global market is segmented into instruments, consumables, and services. The instruments segment is estimated to account for the largest market share of the global market in 2017. Factors driving the growth of this segment include the extensive use of instruments and advances in technology to develop innovative instruments.

By method, the market is classified into phenotypic methods, proteomics-based methods, and genotypic methods. The phenotypic methods segment is estimated to account for the largest share of the global microbial identification market. The large share of this segment can be attributed to features like cost-effectiveness, ease of use, and ability to deliver results rapidly which lead to their increased adoption across different end users.

On the basis of end user, the microbial identification market is segmented into hospitals, diagnostic laboratories, and blood banks; food manufacturing companies; beverage manufacturing companies; pharmaceutical companies and CROs; and other end users. The hospitals, diagnostic laboratories, and blood banks segment is estimated to account for the largest share of the global market. Rising prevalence of various infectious diseases coupled with periodic outbreaks of pandemics and epidemics are major factors driving the growth of this end user segment.

Companies Mentioned:

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Microbial Identification Market, By Product And Service

7 Microbial Identification Market, By Method

8 Microbial Identification Market, By Application

9 Microbial Identification Market, By End User

10 Microbial Identification Market, By Region

11 Competitive Landscape

12 Company Profiles

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/z8hv3v/microbial

Media Contact:


Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


These press releases may also interest you

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...



News published on and distributed by: